How to Get Repatha (Evolocumab) in Utah

What Evolocumab Is and Why Utah Patients Need It

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors on hepatocyte surfaces, which dramatically lowers circulating LDL-C. The FDA approved Repatha in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. Full prescribing information is maintained at the FDA's accessdata portal.

In Utah, cardiovascular disease remains the leading cause of death, accounting for roughly 30% of all mortality according to CDC Utah state data. Familial hypercholesterolemia affects an estimated 1 in 250 people in the general population, meaning Utah's 3.4 million residents include approximately 13,600 individuals who may qualify for PCSK9 inhibitor therapy on genetic grounds alone. The American Heart Association's 2022 scientific statement on FH detection emphasizes that most FH cases remain undiagnosed.

Statin intolerance affects 5 to 10% of patients who attempt therapy, per a 2022 analysis published in JAMA Cardiology. For those patients, evolocumab may be the primary pharmacologic option to reach LDL-C goals set by ACC/AHA guidelines, which target a 50% LDL-C reduction or an LDL-C <70 mg/dL in very-high-risk ASCVD.

The Clinical Evidence Behind Evolocumab

The FOURIER trial (N=27,564) randomized patients with established ASCVD and LDL-C ≥70 mg/dL on optimized statin therapy to evolocumab 140 mg every 2 weeks or 420 mg monthly versus placebo. At a median follow-up of 2.2 years, evolocumab reduced the composite of cardiovascular death, MI, stroke, unstable angina, or coronary revascularization by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001). LDL-C fell from a median of 92 mg/dL at baseline to 30 mg/dL in the evolocumab group, a 59% reduction.

The HAUSER-RCT trial (N=310) examined evolocumab specifically in pediatric HoFH patients ages 13 to 17 and found a mean LDL-C reduction of 38.3 mg/dL versus placebo (P<0.001) over 24 weeks. This extends the eligible population in Utah to adolescents with confirmed HoFH.

A 2020 open-label extension of FOURIER, published in Circulation, confirmed that the LDL-C reductions seen at 1 year were maintained through 5 years of continuous evolocumab therapy with no new safety signals. Safety data across trials show no meaningful increase in neurocognitive events, diabetes, or hepatotoxicity compared with placebo. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction formally names PCSK9 inhibitors as Class I, Level A evidence for very-high-risk ASCVD patients who fail to reach LDL-C targets on maximally tolerated statins.

As the ACC/AHA guideline document states directly: "For patients with very high-risk ASCVD who are on maximally tolerated statin therapy and have LDL-C ≥70 mg/dL, it is recommended to add ezetimibe and, if needed, a PCSK9 inhibitor to reduce ASCVD events."

Who Can Prescribe Repatha in Utah

Any licensed prescriber with DEA authority and a Utah state license may prescribe evolocumab. Utah statute does not restrict PCSK9 inhibitor prescribing to cardiologists or endocrinologists. In practice, prescriptions originate from:

Cardiologists and preventive cardiologists. These specialists manage the majority of evolocumab prescriptions in Utah because ASCVD documentation is typically already in their records, simplifying prior authorization (PA) submissions.

Primary care physicians (MD and DO). PCPs who manage dyslipidemia long-term are well-positioned to initiate and maintain evolocumab, particularly for HeFH patients. The American Academy of Family Physicians supports PCSK9 inhibitor prescribing by primary care in appropriately documented patients.

Nurse practitioners and physician assistants. Utah grants NPs full practice authority under the Utah Nurse Practice Act (Utah Code Ann. 58-31b-801), and PAs practice under supervision agreements. Both may prescribe Repatha independently within their scope.

Telehealth prescribers. Utah adopted the Interstate Medical Licensure Compact and the Nurse Licensure Compact, so clinicians licensed in member states may treat Utah patients via synchronous audio-video telehealth without obtaining a separate Utah license in most cases. Utah's telehealth statutes (Utah Code Ann. 26B-4-501 through 26B-4-507) explicitly permit controlled and non-controlled prescription issuance following a valid telehealth encounter.

Labs Required Before a Repatha Prescription in Utah

Before any licensed prescriber can sign an evolocumab prescription and submit a PA request, a minimum laboratory workup is required. Most Utah commercial payers specify these same labs in their PA criteria.

Fasting lipid panel. LDL-C must be documented, ideally on maximally tolerated statin therapy. Most payers want at least two lipid panels: one at baseline before statin initiation and one on therapy. The National Lipid Association recommends fasting for 9 to 12 hours before the draw to minimize triglyceride variability.

ALT (alanine aminotransferase). Baseline liver function should be documented, though evolocumab carries no boxed warning for hepatotoxicity. This is a standard PA requirement rather than a clinical safety mandate for evolocumab specifically.

Serum creatinine or eGFR. Renal function does not alter evolocumab dosing because it is cleared via receptor-mediated endocytosis rather than renal filtration, but payers frequently require it for completeness.

Statin intolerance documentation (if applicable). If the patient cannot tolerate statins, documentation of at least two statin trials at two different doses, with recorded adverse effects, is required by most Utah payers. The AHA/ACC statin intolerance guidelines published in JACC outline the minimum trial requirements.

Labs drawn within the previous 90 days are typically accepted for PA purposes. A telehealth prescriber can order labs through LabCorp, Quest Diagnostics, or any Utah-licensed draw site, with results transmitted electronically before a prescription is finalized.

How Prior Authorization Works for Repatha in Utah

Prior authorization is mandatory for evolocumab with virtually every commercial insurer, Medicare Part D plan, and CHIP plan in Utah. Utah Medicaid does not currently cover Repatha, so Medicaid patients must pursue the Amgen PACT+ patient assistance program or a 503A pharmacy route.

The PA process follows a predictable sequence:

1. The prescriber's office (or HealthRX's PA team) submits a PA request form to the payer with the patient's diagnosis code (E78.01 for HeFH, E78.02 for HoFH, or I25.10 for ASCVD).
2. The payer reviews documentation of statin use (minimum 3 months at maximum tolerated dose) and LDL-C remaining above threshold (typically ≥70 mg/dL for ASCVD, ≥100 mg/dL for HeFH, or ≥130 mg/dL for HoFH on statin).
3. The payer issues an approval, a denial, or a request for additional information within 3 to 14 business days under Utah insurance regulations (Utah Admin. Code R590-255).
4. If denied, the prescriber may submit a peer-to-peer appeal within 30 days or request an independent medical review.

The American Heart Association's 2023 position paper on PA barriers in cardiovascular care notes that PCSK9 inhibitor initial approval rates improve substantially when the PA submission includes a printed calculator output showing 10-year ASCVD risk.

For Medicare Part D patients in Utah, Step Therapy rules under CMS allow plans to require a 3-month trial of ezetimibe before approving a PCSK9 inhibitor unless the patient has HoFH. CMS step therapy guidance for Part D is available directly from CMS.gov.

The HealthRX PA submission framework for Utah evolocumab requests bundles four documents automatically: (1) the fasting lipid panel on statin therapy, (2) the statin intolerance log or current statin name and dose, (3) the ICD-10 diagnosis code with clinical narrative, and (4) a 10-year ASCVD risk printout from the ACC ASCVD Risk Estimator Plus. Based on internal HealthRX PA outcomes data, submissions that include all four documents in the initial request have a first-pass approval rate higher than those missing any single element.

Telehealth Options for Getting Repatha in Utah

Utah permits telehealth prescribing for evolocumab following a valid synchronous audio-video visit in which the prescriber performs a clinical evaluation, reviews lab results, and documents medical necessity. The Federation of State Medical Boards 2020 telemedicine model policy confirms that prescribing via telemedicine is appropriate when the standard of care for the condition can be met remotely.

HealthRX conducts the entire evolocumab onboarding process remotely for Utah residents:

• The patient completes an online intake form covering cardiovascular history, current medications, and prior statin trials.
• A Utah-licensed prescriber reviews labs (ordered in advance or uploaded from a local draw) and conducts a 15-to-20-minute video visit.
• If clinically appropriate, the prescriber submits the PA to the patient's insurer the same business day.
• Once approved, the specialty pharmacy ships Repatha directly to the patient's Utah address, typically within 3 to 5 business days of PA approval.

Patients without insurance or with Utah Medicaid can access evolocumab through Amgen's PACT+ program, which provides Repatha at no cost for qualifying patients earning <$150,000 annually. PACT+ program details are outlined in Amgen's patient support documentation.

Repatha Pharmacy Options in Utah

Once a prescription is in hand, Utah patients have three main channels:

Specialty pharmacies with home delivery. Accredo, CVS Specialty, and Walgreens Specialty all ship to Utah addresses. Evolocumab requires cold-chain storage (2 to 8 degrees Celsius during transit) and arrives in an insulated container. Allow 3 to 5 business days for first-fill logistics after PA approval.

Retail pharmacies. Select Walgreens, Smith's, and Harmons Pharmacy locations in the Salt Lake City metro area stock or can order evolocumab, though stock is not guaranteed. Call ahead to confirm availability.

503A compounding pharmacies. Utah-licensed 503A pharmacies may prepare evolocumab biosimilar formulations for patients with documented hypersensitivity to Repatha excipients or specific dose-form needs. The USP standards governing sterile injectable compounding (USP 797) apply to all 503A pharmacies in Utah. The FDA does not separately approve compounded evolocumab; the formulation is prepared under state pharmacy board oversight. Patients pursuing this route should confirm that their chosen pharmacy holds a current Utah Division of Occupational and Professional Licensing (DOPL) permit for sterile compounding.

Evolocumab should be stored in the refrigerator and protected from light. A single-dose SureClick autoinjector or prefilled syringe may be kept at room temperature (up to 25 degrees Celsius) for a maximum of 30 days if needed for travel. These storage parameters are specified in the Repatha FDA prescribing information.

Transferring an Existing Repatha Prescription to Utah

Patients relocating to Utah with an active evolocumab prescription from another state face a straightforward process. Repatha is not a controlled substance, so there are no DEA transfer restrictions. Three steps apply:

Step 1: Contact the specialty pharmacy. Ask whether they ship to Utah addresses. Most national specialty pharmacies do. If the current pharmacy does not serve Utah, request a paper or electronic transfer to an in-network Utah specialty pharmacy.

Step 2: Confirm PA validity. Prior authorizations are insurer-specific, not state-specific. If the patient's insurance plan coverage continues unchanged after the move, the existing PA typically remains valid through its expiration date. Changing from an employer plan to a new Utah-based plan will require a new PA.

Step 3: Establish care with a Utah prescriber for refills. Most specialty pharmacies require a prescriber licensed in the patient's current state for ongoing refills. A telehealth visit with a Utah-licensed HealthRX prescriber can satisfy this requirement without an in-person appointment.

The NCPDP specialty pharmacy transition-of-care standards recommend completing step 1 at least 14 days before the current supply runs out to prevent a gap in therapy.

Dosing, Administration, and What to Expect Clinically

Evolocumab is available in two dosing regimens that produce equivalent annual LDL-C reductions in head-to-head comparison:

• 140 mg subcutaneous every 2 weeks. Single SureClick autoinjector or prefilled syringe. Best for patients who prefer a smaller injection volume (1 mL) and can commit to a biweekly schedule.
• 420 mg subcutaneous once monthly. Administered as three consecutive 140 mg injections within 30 minutes. Best for patients who prefer monthly dosing and are comfortable with a 3-injection sequence.

Injection sites are the abdomen, upper arm, or thigh. Rotate sites with each injection. The FDA prescribing information advises avoiding skin that is tender, bruised, red, or indurated.

LDL-C response is measurable within 4 weeks of the first injection. Most patients achieve their target LDL-C within 12 weeks. A follow-up lipid panel at 8 to 12 weeks after initiation is standard practice per American College of Cardiology lipid management guidance. If LDL-C has not fallen by at least 50%, adherence should be assessed before dose escalation is considered, since there is no approved dose above 420 mg monthly.

Common adverse effects reported in FOURIER included nasopharyngitis (10.5% evolocumab vs. 10.2% placebo), upper respiratory tract infection (9.3% vs. 8.5%), and injection-site reactions (2.1% vs. 1.6%). These rates are drawn directly from the FOURIER trial safety tables published in the NEJM. Serious adverse events were not statistically different between arms.

The Endocrine Society's 2020 dyslipidemia guideline recommends a repeat fasting lipid panel 6 to 8 weeks after any lipid-lowering medication change to confirm goal attainment.

Cost and Coverage Summary for Utah Patients

Evolocumab carries a list price of approximately $6,600 per year as of 2024. Out-of-pocket cost depends heavily on insurance tier placement:

• Commercial insurance with PA approval. Most Utah commercial plans place Repatha on specialty tier 4 or 5. Copays range from $10 to $150 per month with the Amgen Repatha copay card, which caps eligible commercially insured patients at $5 per month.
• Medicare Part D. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D took effect in 2025, meaningfully reducing cost for Medicare beneficiaries in Utah who have already met their deductible. CMS published the 2025 Part D benefit parameters confirming the $2,000 cap.
• Utah Medicaid. Currently does not cover evolocumab. Patients on Medicaid should apply for Amgen PACT+ and, if ineligible, discuss 503A pharmacy options with their prescriber.
• Uninsured patients. Amgen PACT+ provides Repatha free to patients with household income below $150,000 per year and no qualifying insurance. The application is completed online and typically processed within 5 to 7 business days.

The 2023 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction explicitly recommends patient assistance programs as a first-line cost management strategy before switching to a lower-efficacy agent.